
ABSTRACT OF THE DISCLOSURE

D3 The invention relates to a method for inhibiting an *in vivo* alloimmune response, and to the use of a soluble recombinant human CD40L protein containing the active binding site with CD40. In particular, a soluble 18KDa recombinant CD40L is used to inhibit an *in vivo* alloimmune response.
